Kentucky joined 43 other states and the District of Columbia in reaching a $105 million settlement with GlaxoSmithKline to resolve allegations that the pharmaceutical manufacturer unlawfully promoted its asthma drug, Advair, and its antidepressant drugs, Paxil and Wellbutrin. The complaint and consent judgment filed today alleges that GSK violated state consumer protection laws by misrepresenting the uses and qualities of these drugs. Kentucky’s share of the settlement is approximately $1.75 million.
“My office will not tolerate misleading marketing by pharmaceutical companies,” Attorney General Conway said. “I will continue to investigate and vigorously pursue cases against drug companies that put profits ahead of public safety and health.”
The consent judgment also requires GlaxoSmithKline to continue its “Patient First” program at least through March of 2019. “Patient First” reduces financial incentives for sales representatives who engage in deceptive marketing. In addition, the judgment requires scientifically trained personnel to be ultimately responsible for developing and approving responses to health care provider questions and for these responses to be unbiased and non-promotional.
In addition to Kentucky and the District of Columbia, the states participating in the settlement were Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin and Wyoming.You can follow Attorney General Conway on Twitter @kyoag or visit the Attorney General’s Facebook page.
Information provided by Daniel Kemp
|< Prev||Next >|